Yangyang Jiang, Jingshu Zhang, Zhichao Jiang, Xiaoyu Liu, Lixin Wang
{"title":"The prognostic value of serum Mg<sup>2+</sup> concentration in patients with heart failure and type 2 diabetes mellitus: a retrospective cohort study.","authors":"Yangyang Jiang, Jingshu Zhang, Zhichao Jiang, Xiaoyu Liu, Lixin Wang","doi":"10.1007/s12020-025-04282-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Epidemiological studies have discovered an inverse correlation between serum Mg<sup>2+</sup> concentration and the risk of developing heart failure (HF) as well as atrial fibrillation (AF) in patients with type 2 diabetes mellitus (T2DM). The prognostic relevance of serum Mg<sup>2+</sup> concentration in patients with HF and T2DM remains unclear.</p><p><strong>Objectives: </strong>To assess the association of serum Mg<sup>2+</sup> concentration with cardiovascular event rates in a retrospective cohort of patients with HF and T2DM.</p><p><strong>Methods: </strong>This study included patients diagnosed with HF and T2DM in First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, from July 2018 to December 2021. The primary endpoint was cardiovascular death or rehospitalization for HF.</p><p><strong>Results: </strong>This study included 216 patients with HF and T2DM. Patients were divided into three groups (T1 [serum Mg<sup>2+</sup> level ≤ 0.8 mmol/L], T2 [0.8 < serum Mg<sup>2+</sup> level ≤ 0.89 mmol/L], T3 [serum Mg<sup>2+</sup> level ≥ 0.9 mmol/L]) based on serum Mg<sup>2+</sup> level. The Kaplan-Meier analysis revealed that the incidence rate of primary endpoint was significantly increased among three groups (P < 0.001). In multivariate Cox regression model, elevated serum Mg<sup>2+</sup> level was considered as a protective factor in the coexistence of T2DM and HF with poor prognosis.</p><p><strong>Conclusions: </strong>Our results indicated that increased serum Mg<sup>2+</sup> concentration may improve long-term prognosis of patients with HF and T2DM.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12020-025-04282-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Epidemiological studies have discovered an inverse correlation between serum Mg2+ concentration and the risk of developing heart failure (HF) as well as atrial fibrillation (AF) in patients with type 2 diabetes mellitus (T2DM). The prognostic relevance of serum Mg2+ concentration in patients with HF and T2DM remains unclear.
Objectives: To assess the association of serum Mg2+ concentration with cardiovascular event rates in a retrospective cohort of patients with HF and T2DM.
Methods: This study included patients diagnosed with HF and T2DM in First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, from July 2018 to December 2021. The primary endpoint was cardiovascular death or rehospitalization for HF.
Results: This study included 216 patients with HF and T2DM. Patients were divided into three groups (T1 [serum Mg2+ level ≤ 0.8 mmol/L], T2 [0.8 < serum Mg2+ level ≤ 0.89 mmol/L], T3 [serum Mg2+ level ≥ 0.9 mmol/L]) based on serum Mg2+ level. The Kaplan-Meier analysis revealed that the incidence rate of primary endpoint was significantly increased among three groups (P < 0.001). In multivariate Cox regression model, elevated serum Mg2+ level was considered as a protective factor in the coexistence of T2DM and HF with poor prognosis.
Conclusions: Our results indicated that increased serum Mg2+ concentration may improve long-term prognosis of patients with HF and T2DM.
期刊介绍：
Well-established as a major journal in today’s rapidly advancing experimental and clinical research areas, Endocrine publishes original articles devoted to basic (including molecular, cellular and physiological studies), translational and clinical research in all the different fields of endocrinology and metabolism. Articles will be accepted based on peer-reviews, priority, and editorial decision. Invited reviews, mini-reviews and viewpoints on relevant pathophysiological and clinical topics, as well as Editorials on articles appearing in the Journal, are published. Unsolicited Editorials will be evaluated by the editorial team. Outcomes of scientific meetings, as well as guidelines and position statements, may be submitted. The Journal also considers special feature articles in the field of endocrine genetics and epigenetics, as well as articles devoted to novel methods and techniques in endocrinology.
Endocrine covers controversial, clinical endocrine issues. Meta-analyses on endocrine and metabolic topics are also accepted. Descriptions of single clinical cases and/or small patients studies are not published unless of exceptional interest. However, reports of novel imaging studies and endocrine side effects in single patients may be considered. Research letters and letters to the editor related or unrelated to recently published articles can be submitted.
Endocrine covers leading topics in endocrinology such as neuroendocrinology, pituitary and hypothalamic peptides, thyroid physiological and clinical aspects, bone and mineral metabolism and osteoporosis, obesity, lipid and energy metabolism and food intake control, insulin, Type 1 and Type 2 diabetes, hormones of male and female reproduction, adrenal diseases pediatric and geriatric endocrinology, endocrine hypertension and endocrine oncology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
